Pre-approval Expanded Access of Retatrutide (LY3437943)

NCT07629401 · Available

Last updated 2026-08-27

This clinical trial provides early access to the experimental drug LY3437943 for patients with a serious or life-threatening condition before it is fully approved by regulatory agencies.

Status Available

Type Expanded access

Who can join Ages 18+ · all sexes

What this study is testing ClinicalTrials.gov NCT07629401 ↗

Description as written by the study sponsor.

Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square meter \[kg/m²\] and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine.

Treatments tested

Retatrutide also known as LY3437943 Drug

Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Obesity-related Complications
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07629401 ↗